iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$16.16 USD
-0.05 (-0.31%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $16.15 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
iTeos Therapeutics, Inc. [ITOS]
Reports for Purchase
Showing records 1 - 20 ( 112 total )
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Updates Expected in 2H24; New PT $46; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Year of Clinical Data Updates and Pipeline Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ITOS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Gearing Up For a Data-Rich 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Late Breaking Abstract Round Up for ESMO 2023
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Belrestotug Watches Partner Dostarlimab Take First
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ESMO 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- SKYSCRAPER, Episode IV: A New Hope
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: iTeos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Belrestotug to Enter Pivotal Study in 2024; New PT $44; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S